Alzamend Neuro, Inc. (ALZN)
Total Valuation
Alzamend Neuro has a market cap or net worth of $85.86 million. The enterprise value is $74.07 million.
Market Cap | 85.86M |
Enterprise Value | 74.07M |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Alzamend Neuro has 93.02 million shares outstanding. The number of shares has increased by 30.31% in one year.
Shares Outstanding | 93.02M |
Shares Change (YoY) | +30.31% |
Shares Change (QoQ) | +0.76% |
Owned by Insiders (%) | 48.58% |
Owned by Institutions (%) | 3.64% |
Float | 50.34M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 7.18 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | 26.62 |
Quick Ratio | 25.25 |
Debt / Equity | 0.00 |
Debt / EBITDA | 0.00 |
Debt / FCF | 0.00 |
Financial Efficiency
Return on equity (ROE) is -92.10%, which is considered low. The company has a ROIC of -8,505.10%.
Return on Equity (ROE) | -92.10% |
Return on Assets (ROA) | -83.60% |
Return on Capital (ROIC) | -8,505.10% |
Revenue Per Employee | n/a |
Profits Per Employee | -$3.25M |
Employee Count | 3 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (1Y) | n/a |
Total Price Change | -81.80% |
50-Day Moving Average | 1.04 |
200-Day Moving Average | 1.59 |
Average Volume (30 Days) | 1,326,103 |
Short Selling Information
The latest short interest is 1.60 million, so 1.72% of the outstanding shares have been sold short.
Short Interest | 1.60M |
Short % of Shares Out | 1.72% |
Short % of Float | 3.18% |
Short Ratio (days to cover) | 1.10 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -9.67M |
Net Income | -9.75M |
EBITDA | -9.67M |
EBIT | -9.67M |
Earnings Per Share (EPS) | -$0.11 |
Balance Sheet
The company has $11.79 million in cash and no debt, giving a net cash position of $11.79 million or $0.13 per share.
Cash & Cash Equivalents | 11.79M |
Total Debt | 0 |
Net Cash | 11.79M |
Net Cash Per Share | $0.13 |
Book Value | 11.96M |
Book Value Per Share | 0.13 |
Working Capital | 11.96M |
Cash Flow
Operating Cash Flow | -6.31M |
Capital Expenditures | n/a |
Free Cash Flow | -6.31M |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Alzamend Neuro does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Earnings Yield | -11.36% |
FCF Yield | -7.35% |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Buyback Yield | -30.31% |
Shareholder Yield | -30.31% |
Analyst Forecast
The average price target for Alzamend Neuro is $11.48, which is 1,143.77% higher than the current price. The consensus rating is "Buy".
Price Target | $11.48 |
Price Target Difference | 1,143.77% |
Analyst Consensus | Buy |
Analyst Count | 8 |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |